TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma

Inclusion Criteria: \- 1. Histopathologically or clinically confirmed unresectable hepatocellular carcinoma. 2\. Age ≥ 18 years at time of study entry. 3. Child-Pugh scores \<7. 4. Performance status (PS) ≤ 2 (ECOG scale). 5. BCLC stage B, some patients in stage C (Vp2-3). 6. The patient and/or his family agreed to join the clinical trial and sign the informed consent form. Exclusion Criteria: * 1\. Have received TACE or other local treatment for liver cancer (except bridged liver transplantation). 2\. Main portal vein tumor thrombus or complicated with extrahepatic metastasis. 3. Tumor burden≥70% , diffuse liver cancer or tumor is not suitable for mRECIST standard evaluation. 4\. Have received systemic chemotherapy, sorafinib or other targeted therapy or immunotherapy. 5\. Estimated life expectancy of \<3 months. 6. There is a significant decrease in white blood cells and platelets in peripheral blood, severe coagulation dysfunction and can not be corrected：the neutrophil\<1.5×109/L, PLT\<50×109/L. The INR\>2.3. 7\. Renal dysfunction：serum creatinine (SCR) \>176.8 μmol/L（2 mg/dL）or creatinine clearance rate (Ccr) \<30 mL/min. 8\. Serious heart, lung, brain or other important organ diseases. 9. Pregnant or lactating women. 10. cannot cooperate with TACE operation and sign informed consent form.